Loading
A drug approved in the US may take five years to reach a patient in Poland or never reach Nigeria. A live public tracker would show exactly where and why it is stuck.
EFPIA's W.A.I.T. indicator covers Europe annually; nothing comparable exists for Asia, Latin America or Africa, and none tracks the steps between approval and reimbursed availability. The proposal is an automated, open tracker that ingests regulatory decisions, HTA outcomes and reimbursement lists for every oncology drug in at least 60 countries and shows the stage at which each drug is stalled: not filed, under review, approved but not reimbursed, reimbursed with restrictions.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Regulatory divergence between regions.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Regulatory divergence between regions.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Regulatory divergence between regions.
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Regulatory divergence between regions.
Shares ClinicalTrials.gov, Regulatory divergence between regions.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, ClinicalTrials.gov.